Boundless Bio (BOLD) investor relations material

Executive summary

• Entered into a definitive merger agreement with Serapha Bio, Inc.; Serapha stockholders to own ~96.31% of the combined company post-merger, Boundless Bio stockholders ~3.69%.

• Announced a 75% workforce reduction and facility downsizing in anticipation of the merger.

• All legacy clinical programs, including BBI-940, BBI-355, and BBI-825, have been discontinued or wound down due to clinical and market considerations.

• No products approved for sale and no revenue generated to date; operations focused on merger completion.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $72.6 million as of June 30, 2026.

• Net loss for Q2 2026 was $23.7 million, compared to $15.7 million in Q2 2025; net loss for the six months ended June 30, 2026 was $37.2 million, up from $31.4 million year-over-year.

• Operating expenses for Q2 2026 were $24.4 million, up from $17.1 million in Q2 2025, driven by lease termination, impairment, and severance costs.

• Accumulated deficit reached $296.9 million as of June 30, 2026.

Outlook and guidance

• The merger with Serapha Bio is expected to close in Q4 2026, subject to stockholder and regulatory approvals and Serapha raising at least $200 million in new financing.

• Upon closing, the combined company will focus on SERP-01 for Alpha-1 Antitrypsin Deficiency and discontinue Boundless Bio's legacy programs.

• A special cash dividend of $44–$48 million is expected to be paid to pre-merger stockholders, subject to closing adjustments.

• If the merger is not completed, strategic alternatives including liquidation may be considered.